Hemp Research — Page 99

Peer-reviewed industrial hemp research papers, sorted by publication date. Browse the latest findings on hemp cultivation, processing, materials science, biomedical applications, and regulatory science from PubMed, OpenAlex, and other indexed sources.

Oral Abstracts (2022)

Peer-reviewed industrial hemp research published in Journal of Intellectual Disability Research (2022).

Cannabidiol promotes neurogenesis in the dentate gyrus during an abstinence period in rats following chronic exposure to methamphetamine (2021)

Abstract Chronic methamphetamine (meth) abuse can lead to certain deficits in the hippocampal function by affecting the hippocampal neurogenesis and plasticity. To determine whether cannabidiol (CBD) can promote proliferation and maturation of neuronal progenitor cells, this study investigated the CBD effect on neurogenesis in the hippocampal dentate gyrus (DG) following chronic exposure to meth in rats. The rats received 2 mg/kg of meth twice a day for ten days. Next, immunofluorescence was per

Divergent input patterns to the central lateral amygdala play a duet in fear memory formation (2024)

Somatostatin (SOM)-expressing neurons in the central lateral amygdala (CeL) are responsible for fear memory learning, but the circuit and molecular mechanisms underlying this biology remain elusive. Here, we found that glutamatergic neurons in the lateral parabrachial nucleus (LPB) directly dominated the activity of CeL<sup>SOM</sup> neurons, and that selectively inhibiting the LPB<sup>Glu</sup>→CeL<sup>SOM</sup> pathway suppressed fear memory acquisition. By contrast, inhibiting CeL-projecting

A Case Study on Bipolar Affective Disorder Current Episode Manic Without Psychotic Symptoms (2023)

Mood disorders are the second most common condition and can repeat for a variety of reasons. Bipolar mood disorders can cause severe manic and depressed episodes that, if not adequately treated, can result in substantial social and personal problems. This study used a single case study approach and was qualitative in nature. A patient with bipolar affective disorder without psychotic symptoms participated in the trial. A case history form and a mental state assessment instrument were used to gat

Prevalence &amp; Psychiatric Correlates of Illicit Substance Use in UK Undergraduate students (2023)

This study examined the prevalence of illegal drug use in UK students and motivators behind such behaviour. Additionally, we explored possible relationships between substance use, psychosocial motivators, and psychiatric distress. N=543 students completed online measures of substance use, anxiety, depression, perceived stress, insomnia. A series of reasons behind their use were ranked based on importance. Reported cannabis, cocaine, nitrous oxide, ketamine and MDMA use were most prevalent based

Effects of Inhaled Tobacco and Cannabis Co-Use on Respiratory Health and Tobacco Cessation: An Official American Thoracic Society Research Statement (2025)

<b>Background:</b> Tobacco and cannabis are among the most widely used substances globally, and rates of co-use are on the rise. Understanding the impact of inhaled tobacco-cannabis co-use on health outcomes and tobacco cessation is critical for guiding patients and clinicians. <b>Objectives:</b> To summarize the existing evidence, identify knowledge gaps, and prioritize research questions related to effects of inhaled tobacco-cannabis co-use on tobacco cessation and lung health. <b>Methods:</b>

Integrating Human Brain Proteomic Data with Genome-Wide Association Study Findings Identifies Novel Brain Proteins in Substance Use Traits (2022)

Background: Despite the growing number of genetic risk loci identified for substance use traits (SUTs), the impact of these loci on protein abundance and their potential as therapeutic targets are unknown. Methods: To address this, we performed a proteome-wide association study (PWAS) by integrating human brain proteomes from discovery (Banner; N = 152) and validation (ROSMAP; N = 376) datasets with genome-wide association study (GWAS) summary statistics for 4 SUTs. The sample comprised 4 GWAS o

The Wellcome Trust: new funding for mental health science (2023)

The Wellcome Trust is one of the world's largest health research funders. The charity has committed to spend £16 billion over the coming decade (2022-2032) on just four priorities. First, to fund curiosity-driven basic research on any topic that advances understanding of life, health and well-being, through thrice-yearly open schemes available to researchers at different career stages. Second, third and fourth, to address three global health challenges that are in urgent need of scientific solut

Should gastroenterologists prescribe cannabis? The highs, the lows and the unknowns (2023)

Cannabis, commonly known as marijuana, is a drug extracted from the <i>Cannabis</i> plant known for its psychotropic and medicinal properties. It has been used for healing purposes during ancient times, although its psychoactive components led to its restricted use in medicine. Nonetheless, cannabis is found to have modulatory effects on the endocannabinoid system exhibiting its medicinal role in the gastrointestinal (GI) system. Emerging animal and human studies demonstrate the influential effe

Varied Presentations of Pediatric Patients With Positive Cannabinoid Tests (2022)

Our data showed a significant increase in the number of cases since the legalization of cannabis in 2016, supporting the need for ED physicians to become more familiar with cannabis intoxication and its complications. The presentations of these patients can vary greatly. Common presentations include suicidal ideation, nausea/vomiting, AMS, and trauma with vital sign abnormalities including tachycardia and hypertension. Physicians should continue to consider cannabis use when evaluating these ped

Assessing the biobehavioral effects of ultramicronized-palmitoylethanolamide monotherapy in autistic adults with different severity levels: a report of two cases (2024)

Despite promise of its supplementation as both monotherapy and add-on treatment in autism spectrum disorder (ASD), the biobehavioral effects of Palmitoylethanolamide (PEA) in autistic adults have never been explored so far. We discussed the cases of two autistic adults with different degrees of severity (level 1 and level 2) presenting with symptoms of psychic distress, who were treated with ultramicronized-PEA (um-PEA) 600 mg/day monotherapy for a sustained period of 4 months. The level 1 autis

Controlled Drugs, Use, Abuse and Youth: A Meaningful, Yet Evolving Relationship (2022)

Abstract Psychoactive substances take a functional role in the management of emotional and social life of humankind. However, the bond between mind-altering substances and their users or potential users is of changing nature, since the diversity and the accessibility of these substances, as well as the perception of expected benefits and related risks are constantly evolving. Science and technology have contributed to develop new or more potent drugs. The legal status of drugs has become blurrie

Neuroprotective effect of niacin in a rat model of obesity induced by high-fat-rich diet (2024)

This study investigates the impact of a high-fat-rich diet (HFRD) on behavioral, biochemical, neurochemical, and histopathological studies using the hypothalamus of rats following niacin (NCN) administration. The rats were divided into HFRD and normal diet (ND)-fed groups and administered selected doses of NCN, i.e., 25 mg/mL/kg (low dose) and 50 mg/mL/kg (high dose), for 8 weeks. The grouping of male rats (n = 8) was as follows: (i) Vehicle (Veh) + ND; (ii) ND + NCN (low dose); (iii) ND + NCN (

Age and cannabis co-use moderate experience and perceived benefits of psilocybin (2025)

As psychedelic use increases, understanding how demographic and behavioral factors influence the effects of psychedelics is essential for both research and public health. This cross-sectional study examined 365 current psilocybin users, analyzing differences in acute experiences, psychological outcomes, and substance co-use patterns. Participants were categorized into young (18-25), middle-aged (26–54), and older (55-77) adults. Results showed that younger participants reported significantly mor

Psychedelics and cognitive function: A systematic review (2023)

Introduction: With the progressive advancement of clinical and experimental trials aimed at investigating the pharmacotherapeutic potential of psychedelic substances, there is also the development of other conceptions of use, not only for the treatment of psychiatric disorders, but also for the improvement of emotional/cognitive functions. Objective: The present study is a systematic review of investigations aimed at evaluating the effects of psychedelics on cognitive functions in healthy volunt

Mannosylated fisetin/carveol lipid nanocapsules: brain-targeted dual therapy for modulation of epileptogenesis and cognitive deficits (2025)

Pharmacological treatment of epilepsy is challenged by several barriers with the blood brain barrier (BBB) imposing the utmost restrictions to brain drug delivery. Antiepileptic drugs aim to reduce seizures frequency and severity while exerting minimal toxic effects. Herein, the merits of phytomedicine and brain targeted nanocarriers were combined for the control of seizures in a chronic epilepsy model. Fisetin (FS); a polyphenol and carveol (CAR); a limonene monoterpenoid were selected for thei

Defining Treatment‐Resistant Bipolar Depression: Recommendations From the ISBD Task Force (2025)

This consensus definition aims to provide clarity for clinical trials, improve consistency in research, and guide treatment approaches and inform regulatory pathways. It represents a foundational step in addressing the unmet needs in TRBD and promoting the development of innovative therapeutic strategies. Future efforts will focus on adapting the definition to better align with real-world clinical challenges and optimize patient care.

Innovative, complementary and alternative therapy in inflammatory bowel diseases: A broad 2020s update (2022)

Inflammatory bowel diseases (IBD) are chronic disabling conditions with a complex and multifactorial etiology, which is still not completely understood. In the last 20 years, anti-TNF-α antagonists have revolutionized the treatment of IBD, but many patients still do not respond or experience adverse events. Therefore, new biological therapies and small molecules, targeting several different pathways of gut inflammation, have been developed of which some have already been introduced in clinical p